The envelope glycoproteins (Env) represent a critical component of a successful antibody-mediated human immunodeficiency virus type 1 (HIV-1) vaccine. However, immunization with soluble Env was reported to induce short-lived antibody responses, suggesting that Env has unusual immunogenic properties. Here, we directly compared the magnitude and durability of B-cell responses induced by HIV-1 Env and an unrelated soluble viral protein, influenza virus hemagglutinin (HA), in simultaneously inoculated macaques. We demonstrate robust peak responses followed by rapid contraction of circulating antibody and memory B cells for both antigens, suggesting that short-lived responses are not unique to HIV-1 Env but may be a common feature of soluble protein vaccines.
Studies in human trials indicate that vaccines based on recombinant, soluble human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Env) stimulate short-lived antibody (Ab) responses, compared with the responses elicited by several effective antiviral vaccines in clinical use [1] [2] [3] [4] . This has raised questions about the intrinsic immunogenicity of Env and whether B cell responses induced by Env-based vaccine candidates are unusual in their immunological properties. Factors that have been suggested to affect the quality of the elicited immune response are the high density of N-linked glycans on Env and their potential interactions with lectinexpressing antigen-presenting cells, which may affect downstream events [5] . Furthermore, in vitro experiments suggest that the capacity of Env to interact with cells expressing the primary viral receptor, CD4, or the coreceptors, CCR5 or CXCR4, may modulate T-cell function (reviewed in) [6] , but a direct effect of this in vivo has not been shown [7] .
To investigate whether HIV-1 Env is an unusual antigen in terms of the durability of the elicited B-cell response, we inoculated macaques with similarly produced soluble HIV-1 Env and influenza virus hemagglutinin (HA) proteins in adjuvant and monitored the elicited response over an 8-month period. HA was chosen because it is another highly vaccine-relevant viral glycoprotein that is less glycosylated and lacks the capacity to interact with CD4. After simultaneous immunization of the monkeys with Env in one leg and HA in the other, we determined circulating Ab binding titers, frequencies of memory B cells, and bone marrow plasma cell reactivity. The results reported here suggest that the rapid decline in the B-cell responses from peak levels observed after boosting is not a unique property of the response induced by HIV-1 Env but may be a general feature of responses induced by soluble protein antigen immunizations.
METHODS

Animals
Female cynomolgus macaques (Macaca fascicularis; age, approximately 9 years; designated F135-F140) of Chinese origin were housed at the Astrid Fagraeus Laboratory at Karolinska Institutet. Housing and care procedures were in compliance with the guidelines of the Swedish Board of Agriculture. All procedures were approved by the local ethics committee on animal experiments. Samplings of blood, bone marrow, and mucosal lavage were performed as previously described [8] .
Immunogens
Soluble HIV-1 gp140 trimers (gp140-F) and mutant Env trimers (gp140-F-423/425/431) were described previously [7, 9] .
Plasmids expressing soluble influenza virus HA1 based on GenBank accession numbers ACP44189, ACA28844, ABF21272, and ACS71642 were designed and produced using essentially the same protocol as described for Env [10] . Briefly, the proteins were produced via transient transfection of 293-F cells, using 293Fectin (Invitrogen). On day 5 of culture, the supernatants were cleared, and the proteins were purified with lentil lectin, after which nickel-chelation chromatography was performed. Following buffer exchange to phosphate-buffered saline (PBS), the proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for assessment of their integrity and purity (Supplementary Figure 1) . On the basis of the seroreactivity profile of the 3 HA variants in prebleed samples from the animals, the A/ Brisbane/59/2007/(H1N1) variant (GenBank accession number ACA28844) was chosen (Supplementary Figure 2) . HA1 and gp140-F proteins used as probes in the enzyme-linked immunosorbent spot (ELISpot) assay were biotinylated according to the manufacturer's instructions (Avitag). Ovalbumin (Sigma), used as a negative control, was biotinylated via ester linkage with sulfo-N-hydroxysuccinimide, according to the manufacturer's instructions (Sigma).
Immunizations
Immunizations were performed in the quadriceps muscle in a total volume of 0.5 mL at 0, 4, and 33 weeks. The Env and HA antigens were given in equal molar amounts, in which each macaque received 51 μg of HA and 100 μg of Env. All proteins were administered with 50 μg of AbISCO-100 (Isconova) and 250 μg of CpG-ODN-2395 (Invivogen) in PBS.
Assessment of Immunogenicity
B-cell responses were determined by enzyme-linked immunosorbent assay (ELISA) and ELISpot assay, as described elsewhere [7, 8, 11] . Briefly, memory B-cells were differentiated to antibody-secreting cells by culturing with 10 μg/mL pokeweed mitogen (Sigma), 1/10 000 SAC (Sigma), and 5 μg/mL CpG ODN 10 103 (Coley) [8] . On day 4 of culture, the cells were washed and transferred to ELISpot plates coated with antihuman-Fcγ ( Jackson Immunoresearch) and incubated overnight. Antigen-specific and total immunoglobulin G (IgG) secreting B-cells were determined by incubating the plates with biotinylated HA or Env and anti-human Fcγ, respectively ( Jackson Immunoresearch). Spots were visualized by addition of streptavidin conjugated to alkaline phosphatase, followed by BCIP/NBT. After washing extensively in water, the plates were left to air dry overnight. Spots were evaluated on an Immunospot analyzer (Cellular Technology). Enumeration of bone marrow plasma cells was performed via direct plating onto ELISpot plates without prior stimulation.
Ab production from long-lived plasma cells was evaluated by culturing the mononuclear cell fraction of macaque bone marrow for 1-3 weeks, with an optimum culture time of approximately 2 weeks. The cells were incubated at 37°C in 5% CO 2 in 48-well plates at 1 million cells/mL in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, 100 μM streptomycin, 2% HEPES, and 50 mM β-mercaptoethanol.
Antibody titers in plasma and culture supernatants were determined by ELISA. Briefly, MaxiSorp 96-well plates (Nunc) were coated with recombinant gp140-F, HA, or goat antihuman Fcγ ( Jackson Immunoresearch) overnight. Samples were added in a dilution series, and IgG was detected by addition of horseradish-peroxidase-conjugated goat-anti rhesus Fcγ (Nordic Immunological Laboratories) and TMB+ (Invitrogen). The optical density (OD) was read at 450 nm, and half-maximal binding titers (designated as OD 50 titers) were calculated for plasma samples and antibody concentrations, using a rhesus IgG standard (Southern Biotech), for culture supernatants.
As an indicator for antibody maturation, plasma antibodies were subjected to a chaotropic ELISA wash assay using NaSCN. The samples were treated as for a standard ELISA with an extra 10-minute incubation period with 1.5, 3, or 4.5 M NaSCN or PBS, following sample binding to the ELISA plate. The avidity index was calculated as [treated/PBS] × 100.
Statistical analysis
Statistics was evaluated using GraphPad prism software, version 4 (GraphPad Software). Ab half-lives were calculated from 1-phase exponential decay curves. Correlations were calculated by assuming a nonparametric distribution (Spearman r) on log 10 -transformed data. Correlation lines were generated with linear regression. Differences between groups and time points were evaluated using 2-way analysis of variance with Bonferroni posttests. Statistical significance was defined as a P value of ≤ .05.
RESULTS
To directly compare the durability of B-cell responses elicited by soluble HIV-1 Env with those of another vaccine-relevant soluble protein immunogen, influenza virus HA1, we immunized 6 cynomolgus macaques with HIV-1 Env in the right leg and influenza virus HA in the left leg ( Figure 1 ). All protein batches were produced in the same manner, and the purity was assessed by SDS-PAGE (Supplementary Figure 1) . Macaques were inoculated 3 times (at weeks 0, 4, and 33; Figure 1A ), using a regimen similar to that used for early HIV-1 Env immunization studies [12] and the successful human hepatitis B virus and human papillomavirus vaccine studies. To simultaneously assess the role of in vivo CD4 binding, which was reported to occur during Env immunization of primates [10] , CD4-binding-competent gp140-F Figure 1 . Humoral immune responses following immunization of cynomolgus macaques with recombinant human immunodeficiency virus type 1 (HIV-1) Env or influenza virus hemagglutinin (HA). Six cynomolgus macaques were inoculated with recombinant, soluble HIV-1 Env and influenza virus HA glycoproteins. A, Inoculations were given at 0, 4, and 33 weeks. Blood (red arrows), bone marrow (blue arrows), rectal lavage, and vaginal lavage (green arrows) specimens were obtained at indicated time points. Three macaques were given CD4 binding-competent gp140-F (wild-type; F135-137), and 3 macaques were given CD4 binding-deficient gp140-F-423/425/431 (F138-140). All 6 macaques also simultaneously received HA A/Brisbane/59/ 2007(H1N1). B, There was no difference in the Env-specific plasma antibody titers induced by the 2 Env variants at any time point, as determined by 2-way analysis of variance, followed by Bonferroni posttests. The optical density (OD) was read at 450 nm, and the half-maximal binding titers were designated as OD 50 titers. C and D, Circulating antibody responses to Env (n = 6; red circles) and HA (n = 6; blue circles) were determined over the course of the study (C ), and antigen-specific antibody half-lives were assessed by 1-phase exponential decay calculations between the second and third immunization (D ). E, Antibody maturation, as indicated by a 1.5-M NaSCN wash assay, was determined following the second immunization. F and H, Mucosal responses, presented as antigen-specific immunoglobulin G (IgG) titers of total IgG in the sample, were evaluated from vaginal (F ) and rectal (H ) lavages. G and I, Correlations were determined between the mucosal antibody frequencies and circulating antibody titers by the nonparametric Spearman r analysis. All error bars correspond to the standard error of the mean.
trimers and CD4-binding-deficient gp140-F-423/425/431 trimers [7] were used in 3 animals each. Throughout our experiments, we did not observe any difference in the response to these 2 Env variants ( Figure 1B) , and we therefore grouped all Env-immunized animals together for the subsequent comparisons with influenza virus HA.
We observed high Env-and HA-specific IgG titers in the plasma 2 weeks following the second immunization ( Figure 1C ). The titers declined similarly for both antigens during the subsequent 29-week period before reaching peak levels again following the third immunization ( Figure 1C, 1F , and 1H). The half-lives of the antigen-specific IgG, calculated 6 cultured peripheral blood mononuclear cells (PBMCs), directed against total immunoglobulin G (IgG; black), Env (red), HA (blue), and the negative control, ovalbumin (white circles), were measured by B-cell enzyme-linked immunosorbent spot (ELISpot) assay. B, Frequencies of cells producing antigen-specific IgG, compared with total IgG, were determined. C, Correlations between the frequency of memory B-cells over the 29-week interval between immunization 2 and 3 and half-maximal plasma antigen-specific IgG titers were determined by Spearman r analysis. The optical density (OD) was read at 450 nm, and the half-maximal binding titers were designated as OD 50 titers. D, IgG-expressing bone marrow (BM) resident plasma cells were measured by ELISpot assay for total IgG (black), Env (red), HA (blue), and the negative control, ovalbumin (white circles). E, Frequencies of antigen-specific and total IgG-producing bone marrow plasma cells were calculated. G, Antibody secretion of bone marrow plasma cells specific for total IgG (black), Env (red), and HA (blue) was evaluated by enzyme-linked immunosorbent assay on culture supernatants. H, F, and I, Antigen-specific IgG titers were calculated for the bone marrow plasma cells (H ) and compared to the Env (F ) and HA (I ) frequencies observed in the circulating plasma at 8, 16, and 33 weeks after study initiation (corresponding to 4, 12, and 29 weeks after immunization 2). All error bars correspond to the standard error of the mean. Statistical significance was determined via 2-way analysis of variance and Bonferroni posttests. *P ≤ .05, **P ≤ .01, and ***P ≤ .001.
on Figure 1D ). The kinetics of the response was similar in mucosal lavages ( Figure 1F and 1H) , and there was a high correlation between Ab titers in the plasma and in the mucosal compartments for both Env and HA ( Figure 1G and 1I ). Concurrent with the decline in Ab titers during the 29-week interval, we observed increasing plasma binding strength for both Env-and HA-specific Abs, as determined by a chaotropic ELISA wash assay, suggesting ongoing Ab affinity maturation ( Figure 1E and Supplementary Figure 3) [13] .
To characterize the vaccine-induced responses at the cellular level, we first determined the frequency of antigen-specific memory B-cells by culturing PBMCs in vitro to differentiate them into antibody-secreting cells [8] . Peak levels, 12.4% and 3.3% of the circulating IgG-expressing memory pool for Env and HA, respectively, were measured 2 weeks following the second immunization. During the ensuing 29 weeks, the antigen-specific B-cell frequencies declined similarly to the plasma Ab responses (Figure 2A and 2B ), illustrated by a high correlation between these compartments ( Figure 2C ). The number of Antigen-specific bone marrow plasma cells (measured by B-cell ELISpot analysis; Figure 2D and 2E) and Abproducing capacity (measured by ELISA on supernatants from bone marrow cultures; Figure 2G and H) were stable throughout the 29-week period. Both antigens induced similar magnitudes of bone marrow plasma cells, with approximately 1% of the total IgG pool consisting of antigen-specific IgG. When examining the frequency of antigen-specific bone marrow plasma cells and circulating plasma Abs, they converged at 29 weeks, following the second inoculation ( Figure 2F and 2I ).
DISCUSSION
In this study, we investigated whether B-cell responses elicited by a well-characterized Env immunogen, the soluble YU2-based gp140-F trimers [9] , displayed properties that in some way differed from those induced by another soluble vaccinerelevant protein antigen, influenza virus HA. We used 2 variants of Env: CD4-binding-competent gp140-F (wild-type) trimers and CD4-binding-defective gp140-F-423/425/431 trimers. These variants were previously shown to induce Ab responses of similar magnitude, but the durability of the response was not measured in those studies [7] . Here, we show that the Ab half-lives and the memory B-cell responses induced by these 2 Env variants were also similar.
We also found that HIV-1 Env and influenza virus HA elicited similar levels of both circulating Ab and memory B-cells throughout the study. Peak responses were reached after the second immunization, followed by a contraction of about 1.5 logs over the following 29 weeks. There was a strong correlation between memory B-cell responses and plasma Ab levels, indicating that a majority of the circulating Abs arose from differentiation of antigen-specific memory B-cells to shortlived plasma cells on antigen reexposure, similar to that observed following tetanus toxoid boost [14] . This likely explains the short half-life of the Ab response measured immediately after boost, while the more-stable Ab levels measured at later time points could result from long-lived bone marrow plasma cells. The level of antigen-specific bone marrow plasma cells was stable over the 29 weeks following the second immunization. Furthermore, the frequency of antigen-specific IgG produced from bone marrow cultures converged with the frequencies of antigen-specific IgG titers in circulation when plateau Ab levels were reached, indicating that the frequencies measured in bone marrow shortly following immunization are predictive of long-lived steady-state Ab levels. Unlike the slightly different frequencies of HA-specific and Env-specific memory B-cells measured, the frequencies of Env-and HAspecific bone marrow plasma cells were similar. This may be consistent with a more stringent selection of B-cells to enter the bone marrow compartment [15] .
Collectively, the results reported here show that B-cell responses to 2 unrelated viral protein antigens display similar characteristics in terms of the durability of circulating Ab, memory B-cells, and bone marrow plasma cells after boosting. We conclude that several features of the humoral immune response induced by HIV-1 Env are shared by influenza virus HA and perhaps are representative of responses induced by soluble protein antigens in general. These data highlight the need to evaluate vaccine-induced B-cell responses over longer periods and to better understand the source of circulating Abs induced by vaccination to facilitate the selection of vaccine platforms that induce potent and durable B-cell responses.
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